Abstract
This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the associated risk of ventricular arrhythmia and fibrillation. The molecular characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation. The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to determine structure-activity relations (SAR) within chemical series. More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chemical series is a viable strategy to reduce or eliminate hERG activity. Despite a critical need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.
Keywords: hERG, Ikr, action potential, repolarization reserve, transmural dispersion of repolarization (TDR), QT prolongation, torsades de Pointes (TdP)
Current Topics in Medicinal Chemistry
Title: The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview
Volume: 8 Issue: 13
Author(s): Armando A. Lagrutta, Elena S. Trepakova and Joseph J. Salata
Affiliation:
Keywords: hERG, Ikr, action potential, repolarization reserve, transmural dispersion of repolarization (TDR), QT prolongation, torsades de Pointes (TdP)
Abstract: This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the associated risk of ventricular arrhythmia and fibrillation. The molecular characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation. The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to determine structure-activity relations (SAR) within chemical series. More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chemical series is a viable strategy to reduce or eliminate hERG activity. Despite a critical need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.
Export Options
About this article
Cite this article as:
Lagrutta A. Armando, Trepakova S. Elena and Salata J. Joseph, The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview, Current Topics in Medicinal Chemistry 2008; 8 (13) . https://dx.doi.org/10.2174/156802608785700016
DOI https://dx.doi.org/10.2174/156802608785700016 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Apoptosis Signaling Pathways in Lung Diseases
Medicinal Chemistry Neuromuscular Disorders in Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Interatrial Block in the Modern Era
Current Cardiology Reviews Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease
Current Pharmaceutical Design Modeling Cardiovascular Development: New Approaches are Making In Vitro En Vogue
Current Cardiology Reviews The Hypocretins and their Role in Narcolepsy
CNS & Neurological Disorders - Drug Targets Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Multi Extended Imaging (3DMXI): A New Software for Fetal Evaluation by Three-Dimensional Ultrasonography
Recent Patents on Medical Imaging The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry